CDH17

Chr 8

cadherin 17

Also known as: CDH16, HPT-1, HPT1

The protein is a calcium-dependent cell adhesion molecule that functions as an intestinal proton-dependent peptide transporter and contributes to morphological organization of the liver and intestine. Mutations cause congenital diarrheal disorders with early infantile onset, involving severe gastrointestinal dysfunction. The gene shows autosomal recessive inheritance and is not highly constrained against loss-of-function variants.

Summary from RefSeq, UniProt
Research Assistant →
10
Active trials
31
Pubs (1 yr)
38
P/LP submissions
0%
P/LP missense
0.96
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryCDH17
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
38 unique Pathogenic / Likely Pathogenic· 128 VUS of 199 total submissions
💊
Clinical Trials
10 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.96LOEUF
pLI 0.000
Z-score 1.74
OE 0.70 (0.510.96)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.35Z-score
OE missense 0.95 (0.881.03)
438 obs / 459.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.70 (0.510.96)
00.351.4
Missense OE0.95 (0.881.03)
00.61.4
Synonymous OE1.08
01.21.6
LoF obs/exp: 27 / 38.7Missense obs/exp: 438 / 459.2Syn Z: -0.80
DN
0.73top 25%
GOF
0.7126th %ile
LOF
0.2680th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

199 submitted variants in ClinVar

Classification Summary

Pathogenic37
Likely Pathogenic1
VUS128
Likely Benign9
Benign5
37
Pathogenic
1
Likely Pathogenic
128
VUS
9
Likely Benign
5
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
37
0
37
Likely Pathogenic
0
0
1
0
1
VUS
1
124
3
0
128
Likely Benign
0
7
0
2
9
Benign
0
3
0
2
5
Total1134414180

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CDH17 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

AgingVascular StiffnessVascular Dilation

Acetate and Age-associated Arterial Dysfunction

RECRUITING
NCT05424263Phase PHASE2University of Colorado, DenverStarted 2022-09-29
Calcium Acetate Oral SolutionCalcium Carbonate Oral Suspension
Colorectal Cancer (CRC)

Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

RECRUITING
NCT07152210Phase NAGuangzhou Bio-gene Technology Co., LtdStarted 2025-09-01
CAR-T
ASD

Differences in N-CAD Concentration and Brain Function Between Children With ASD and TD

RECRUITING
NCT07400484Chen LiStarted 2025-12-18
Giant Cell ArteritisTemporal ArteritisClonal Hematopoiesis of Indeterminate Potential

Clonal Hematopoiesis in Giant Cell Arteritis

NOT YET RECRUITING
NCT06244069ASST Fatebenefratelli SaccoStarted 2024-03
Temporal arterial biopsyWhole exome sequencingSingle cell transcriptomics
CDH17-positive Advanced Solid Tumors

Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors

RECRUITING
NCT06820424Phase EARLY_PHASE1920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaStarted 2025-03
Anti-CDH17 CAR-T cells infusion
Gastric Cancer

The Gastric Cancer Foundation: A Gastric Cancer Registry

RECRUITING
NCT01514045Stanford UniversityStarted 2011-04
Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

RECRUITING
NCT03042221University of Colorado, DenverStarted 2016-05-10
Cerebral Aneurysm

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

RECRUITING
NCT04141020Phase PHASE2University of MiamiStarted 2021-10-27
Microsurgical clippingEndovascular treatmentSirolimus
Peri-implantitis

Expression of Epithelial-Mesenchymal Transition Associated Markers in Peri-implant Tissues

RECRUITING
NCT05832541University of BaghdadStarted 2022-08-18
Biliary Tract CancerColorectal CarcinomaGastric Cancer, Metastatic

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

RECRUITING
NCT06937567Phase EARLY_PHASE1Zhejiang UniversityStarted 2024-12-26
CDH17 CAR-T
Clinical Literature
Open Research Assistant →